Although the relatively small size of our cohort limits the generalizability of our findings and the ability to perform a matched cohort analysis, this study is among the first to evaluate outcomes of treatment beyond progression to anti-PD-(L)1 therapy in HCC. This evidence concerns the gene CD274 and hepatocellular carcinoma.